INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
Portfolio Pulse from
Kahn Swick & Foti, LLC is investigating the proposed sale of Intra-Cellular Therapies, Inc. to Johnson & Johnson, focusing on the adequacy of the price and process. Shareholders are set to receive $132.00 per share.
January 14, 2025 | 12:00 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Intra-Cellular Therapies is under investigation by Kahn Swick & Foti, LLC regarding its proposed sale to Johnson & Johnson for $132 per share. The investigation focuses on the fairness of the price and process.
The investigation by Kahn Swick & Foti, LLC could impact the perception of the fairness of the proposed sale price, potentially affecting shareholder sentiment and the stock price. However, the outcome of the investigation is uncertain, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
Johnson & Johnson is involved in the proposed acquisition of Intra-Cellular Therapies, which is being investigated for the adequacy of the price and process.
The investigation into the acquisition process may affect Johnson & Johnson's acquisition strategy and timeline, but the direct impact on JNJ's stock price is likely limited in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70